Erratum by unknown
Reference
1 De Francisco ALM, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D, On Behalf of The BA16260
Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anae-
mia in patients with chronic kidney disease on dialysis: a randomized, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006; 60:
1687–96.
Original article ‘The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia:
comparison of data from two national surveys’. Int J Clin Pract 2007; 61: 737–47. Since publication, the fol-
lowing errors have been identiﬁed and are corrected as follows:
Page 737, in the SUMMARY, line 15 should read:
For each condition, approximately 75% or more of patients had BMI ‡ 25 kg/m
2.
Pages 742 and 743, in the RESULTS section, in the Distribution of BMI levels among those with diabetes
mellitus, hypertension and dyslipidaemia, 3rd paragraph, 2nd and 3rd sentences should read:
Approximately 46% of SHIELD and 42% of NHANES hypertensive patients were obese, and 80% of
SHIELD and 76% of NHANES hypertensive patients were overweight or obese. Twenty per cent of SHIELD
and 24% of NHANES hypertensive patients had a BMI < 25 kg/m
2, and therefore would be considered to be
normal weight or underweight (1,13).
Page 743, last paragraph in the RESULTS section, should read:
With regard to dyslipidaemia (Figure 7, Table 2), again, a high prevalence of obesity was found in patients
who had at least one of four criteria for the diagnosis of ‘dyslipidaemia’ (as described above in ‘Deﬁnitions
used to identify conditions’); 38% of SHIELD and 36% of NHANES dyslipidaemic patients were obese, while
75% of SHIELD and 74% of NHANES dyslipidaemic patients were overweight or obese. However, 25% of
SHIELD and 26% of NHANES dyslipidaemic patients were not overweight.
Page 745, in the COMMENT section, 5th paragraph, 1st sentence, should read:
With regard to the analysis of patients with diabetes mellitus, hypertension or dyslipidaemia, whether it
was data collected through a self-reported survey only (such as SHIELD) or through a more detailed evalua-
tion (NHANES), approximately 75% or more of patients with each of these individual metabolic diseases
(often thought to be ‘obesity related’) were overweight or obese, while about 10–25% were not overweight.
Page 743, Table 2, should appear as follows:
Table 2 Relative distributions of body mass index (BMI) in SHIELD and NHANES respondents with diabetes mellitus
(types 1 and 2), hypertension, and dyslipidemia
BMI Category (kg/m
2)
Diabetes mellitus
(types 1 and 2) Hypertension Dyslipidemia
SHIELD NHANES SHIELD NHANES SHIELD NHANES
<18.5 0.5 0.4 0.9 1.7 1.0 0.9
18.5–24.9 12.2 17.1 19.6 21.9 23.8 25.5
25.0–26.9 10.3 9.9 13.7 13.4 15.9 15.1
27.0–29.9 17.8 21.7 20.2 20.7 21.4 22.3
30.0–34.9 26.1 23.2 23.6 23.0 21.3 21.5
35.0–39.9 15.5 13.9 11.7 11.7 9.3 9.5
‡40.0 17.6 13.8 10.4 7.6 7.3 5.1
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Reference
1 Bays HE, Chapman RH, Grandy S for the SHIELD Investigators’ Group. The relationship of body mass index to diabetes mellitus, hyperten-
sion and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007; 61: 737–47.
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Figure 7 Relative distributions of body mass index (BMI) in SHIELD and NHANES respondents with dyslipidemia
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Figure 6 Relative distributions of body mass index (BMI) in SHIELD and NHANES respondents with hypertension
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